CRIS Current Research Information System

PALANDRI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.873
AS - Asia 7.800
EU - Europa 5.668
AF - Africa 466
SA - Sud America 457
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 3
Totale 23.282
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.724
SG - Singapore 2.075
VN - Vietnam 2.046
CN - Cina 1.968
GB - Regno Unito 1.329
IT - Italia 943
SE - Svezia 842
DE - Germania 715
HK - Hong Kong 447
IN - India 401
FR - Francia 375
BR - Brasile 331
RU - Federazione Russa 302
NL - Olanda 222
IE - Irlanda 218
JP - Giappone 202
UA - Ucraina 162
FI - Finlandia 138
KR - Corea 138
ZA - Sudafrica 133
CI - Costa d'Avorio 120
BD - Bangladesh 113
EE - Estonia 103
TG - Togo 98
CA - Canada 93
JO - Giordania 63
CH - Svizzera 57
BG - Bulgaria 54
PH - Filippine 51
TR - Turchia 48
BE - Belgio 47
AR - Argentina 41
PL - Polonia 39
TH - Thailandia 39
NG - Nigeria 36
ID - Indonesia 35
TW - Taiwan 34
MX - Messico 31
AT - Austria 25
IQ - Iraq 25
EC - Ecuador 24
IR - Iran 24
ES - Italia 21
CL - Cile 16
PK - Pakistan 16
SC - Seychelles 16
CZ - Repubblica Ceca 14
SA - Arabia Saudita 13
AU - Australia 12
MA - Marocco 11
VE - Venezuela 11
CO - Colombia 10
ET - Etiopia 10
GR - Grecia 10
LB - Libano 10
LT - Lituania 10
PY - Paraguay 10
AE - Emirati Arabi Uniti 9
RO - Romania 9
EG - Egitto 8
KE - Kenya 8
UZ - Uzbekistan 8
DZ - Algeria 7
PE - Perù 7
DK - Danimarca 6
IL - Israele 6
LV - Lettonia 6
MY - Malesia 6
TN - Tunisia 6
LY - Libia 5
CR - Costa Rica 4
GT - Guatemala 4
JM - Giamaica 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
HR - Croazia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
CY - Cipro 2
GH - Ghana 2
KG - Kirghizistan 2
MD - Moldavia 2
NO - Norvegia 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
BB - Barbados 1
BS - Bahamas 1
CG - Congo 1
DO - Repubblica Dominicana 1
GA - Gabon 1
Totale 23.264
Salva come PNG Salva come JPEG
Città #
Singapore 1.432
Southend 1.166
Ashburn 931
Fairfield 820
Chandler 741
San Jose 542
Hong Kong 427
Dong Ket 414
Seattle 402
Ho Chi Minh City 392
Houston 391
Hanoi 389
Wilmington 374
Woodbridge 372
Beijing 318
Cambridge 306
Princeton 279
Ann Arbor 247
Santa Clara 245
Hefei 239
Dublin 218
Bologna 187
Boardman 176
Tokyo 168
Dallas 154
Lauterbourg 141
Los Angeles 140
Nanjing 128
New York 123
Abidjan 120
Helsinki 115
Westminster 115
Seoul 113
Lomé 98
Padova 97
Milan 84
Council Bluffs 80
Jacksonville 80
Jinan 74
Buffalo 69
Berlin 68
Munich 65
Amman 62
Shenyang 61
Bremen 60
Turin 60
Saint Petersburg 56
Haiphong 53
Sofia 53
São Paulo 52
Da Nang 51
Frankfurt am Main 49
Brussels 46
Redondo Beach 46
Bern 45
Hyderabad 44
San Diego 44
Falls Church 42
Redmond 38
Shanghai 38
Changsha 37
Guangzhou 36
Abeokuta 33
Nanchang 33
Cornaredo 32
Falkenstein 32
Rome 31
Orem 30
Warsaw 30
Chicago 29
Medford 29
Zhengzhou 29
Hangzhou 28
Jiaxing 26
Johannesburg 26
Montreal 26
Toronto 26
Bengaluru 25
London 25
Nuremberg 25
Tianjin 25
Des Moines 24
Hebei 24
Florence 23
Biên Hòa 22
Phoenix 22
Redwood City 22
Chengdu 21
Can Tho 20
Dearborn 20
Jakarta 20
Norwalk 20
Haikou 18
San Francisco 18
Burdur 17
Boston 16
Olalla 16
Stockholm 16
Brooklyn 15
Clifton 15
Totale 14.922
Salva come PNG Salva come JPEG
Nome #
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 307
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 299
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 280
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 268
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 263
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 253
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 247
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 245
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 229
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 226
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 221
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. 214
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 214
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 213
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 213
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 212
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 207
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 207
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 206
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 204
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 203
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 199
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 198
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 196
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 191
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 191
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 189
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 189
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 188
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 188
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 186
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 186
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 185
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 184
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 184
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 181
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 181
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability 180
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. 180
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 180
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 179
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 175
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 175
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 170
The “vesicular intelligence” strategy of blood cancers 170
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 169
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 168
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 167
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 167
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 166
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 166
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 164
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 164
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 163
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 161
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 159
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 159
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 159
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 159
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 159
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 158
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 156
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 155
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 153
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 153
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 152
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 149
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 147
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 146
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 146
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 145
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 145
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 142
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 142
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 142
Diagnosis and classification of the risk 141
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 141
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance 140
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 140
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 140
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 140
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 139
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 139
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 138
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 138
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 136
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 136
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 135
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 134
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 133
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 133
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 132
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 129
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 129
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 129
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 127
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 126
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 126
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib 126
Totale 17.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.993
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021679 0 0 0 0 0 0 0 0 0 0 0 679
2021/20222.634 210 66 147 281 219 144 56 192 96 268 501 454
2022/20232.919 338 441 176 391 194 243 88 167 477 93 195 116
2023/2024909 57 135 55 87 63 186 56 61 33 67 56 53
2024/20253.256 163 421 260 279 367 166 233 132 86 298 137 714
2025/20267.710 579 610 718 509 824 420 700 456 1.654 628 301 311
Totale 23.766